You may have noticed vaginal dryness in your late forties. Then, around the same time, a pattern of urinary tract infections that never quite went away. Then some discomfort during sex that was not there before. Then a sudden urgency to reach the bathroom that you cannot always control.
These feel like four separate problems. They are not. They share one root cause, one name, and one treatment path.
The medical term is Genitourinary Syndrome of Menopause, or GSM. This post explains what it is, why oestrogen decline causes all these symptoms in the same tissue at the same time, and what the evidence says about managing each level of severity.
For more on this, read our guide on Bleeding After Sex in Menopause.
What this post covers
- Why GSM replaced the older term “vulvovaginal atrophy”
- The tissue changes that produce every GSM symptom
For more on this, read our guide on Discharge After Menopause.
- Why Indian women often experience GSM earlier than global averages suggest
- Four levels of management: non-hormonal support, vaginal oestrogen, DHEA, systemic MHT
- Nutrition that supports the tissue environment treatment is trying to restore
- Pelvic floor physiotherapy: the most underused intervention for GSM
- When to bring this to your OB-GYN
This post connects four topics already covered in detail on Menolia: Vaginal Dryness, Menopause and UTIs, Sex and Libido After Menopause, and Menopause Painful Intercourse. If you are experiencing any of those symptoms and wondering why they appeared together, this is the explanation.
What is GSM?
GSM was formally named in 2014 by the International Society for the Study of Women’s Sexual Health (ISSWSH) and the North American Menopause Society (NAMS). The lead consensus paper, authored by Portman and Gass, proposed replacing the older term “vulvovaginal atrophy” (VVA) because that term captured only the vaginal component and was considered too clinical and too stigmatising for women to comfortably raise with their doctors.
The new definition is broader. GSM covers symptoms and signs related to the decrease in oestrogen and other sex steroids affecting the labia majora and minora, clitoris, vestibule and introitus, vagina, urethra, and bladder. In plain terms: every tissue in the genital and urinary tract contains oestrogen receptors, and every part of that tract is affected when oestrogen falls.
For more on this, read our guide on Painful Sex in Perimenopause. The symptom domains break into three areas:
Vaginal: dryness, burning, irritation, discharge changes, reduced natural lubrication, loss of vaginal elasticity, a shorter or narrower vaginal canal
For more on this, read our guide on Menopause Skin Dryness & Collagen Loss. Urinary: urgency, increased frequency, burning during urination, recurrent urinary tract infections, stress incontinence (leaking with a cough or sneeze), urge incontinence
Sexual: discomfort or pain during intercourse, reduced arousal and lubrication, post-coital spotting
GSM is not uncommon. The VIVA survey, a large multicentre study by Nappi and Kokot-Kierepa published in Maturitas (2012), found that over 50 percent of postmenopausal women experience at least one GSM symptom. Of those, fewer than one in four had discussed the symptom with a doctor. In India, where vaginal and urinary symptoms in midlife carry significant cultural stigma and are rarely discussed even within families, this treatment gap is almost certainly wider.
Why oestrogen decline causes all of this at once
Understanding the mechanism matters because it explains why a single intervention (vaginal oestrogen, for example) can address multiple symptoms simultaneously.
Oestrogen acts through receptors distributed throughout the genitourinary tract. When oestrogen levels fall during perimenopause and after menopause, a predictable set of changes follows in sequence.
Vaginal epithelium thins. A healthy vaginal wall has multiple cell layers thick stratified squamous epithelium. After menopause, without oestrogen stimulation, this can reduce to just a few layers. Thinner epithelium means less transudation (the seeping of fluid through the vaginal wall that produces natural lubrication), more friction, and less structural resilience to minor abrasion.
Vaginal pH rises. A healthy vaginal environment maintains a pH of approximately 3.8 to 4.5. This acidic environment supports Lactobacillus bacteria and inhibits pathogens. The acid comes from lactic acid produced when Lactobacillus ferments glycogen in vaginal epithelial cells. Without oestrogen, glycogen production in those cells falls. Less glycogen means less lactic acid, and pH rises toward 5 to 6.5 or higher. At this elevated pH, the vaginal microbiome shifts: Lactobacillus populations decline, diverse (and less protective) bacterial populations take over, and susceptibility to both bacterial vaginosis and ascending urinary tract infections increases sharply.
Urethral tissue loses integrity. The urethra contains oestrogen receptors throughout its length. Without oestrogen, urethral collagen content falls and muscle tone reduces. Lower urethral closing pressure increases the likelihood of stress incontinence. The structurally weakened urethra also offers less resistance to bacterial entry, which contributes to the recurrent UTI pattern many perimenopausal women experience.
Blood flow to pelvic tissue decreases. Oestrogen promotes angiogenesis and vasodilation in pelvic tissues. As levels fall, the capillary networks supplying the vaginal wall become less responsive. Reduced blood flow means reduced transudation, reduced tissue repair capacity after minor abrasion, and slower recovery from infections.
Collagen is lost progressively. Oestrogen maintains collagen synthesis throughout the body. In vaginal and pelvic floor tissue, collagen loss reduces elasticity and structural support. The vaginal canal may shorten slightly and the introitus can narrow over several years, contributing to discomfort during intercourse even when lubrication has been addressed.
All of these changes occur in the same tissue, driven by the same hormonal shift. This is why the symptoms cluster together, and why treating the root cause addresses the full picture.
Indian women and GSM: why timing matters
Indian women reach natural menopause at an average age of 46 to 48 years, approximately four years earlier than the global average of 51 (Palacios, 2010, Climacteric; Dasgupta and Ray, 2016, Journal of Midlife Health). Lower body mass index, higher parity, and dietary patterns are among the contributing factors. Dhanwal and colleagues (2010, JAPI) documented markers of oestrogen deficiency in Indian women from the mid-forties.
Earlier menopause means earlier onset of GSM. For many Indian women in their late forties, the vaginal and urinary changes associated with GSM are already present while they are still managing children at home, working, and often caring for ageing parents simultaneously. The cultural norm of not discussing these symptoms means the average delay between symptom onset and treatment in India is measured in years, not months.
If you are in your late forties and noticing these changes, the timing is consistent with where oestrogen is in your body, not with anything unusual or alarming about your specific situation.
Management: four levels, one path
Level 1: Non-hormonal support (starting point for all women)
Vaginal moisturisers are not the same as lubricants. A moisturiser is used regularly (two to three times a week, or daily for moderate symptoms) to maintain tissue hydration and restore some of the pH environment over time. Hyaluronic acid formulations and polycarbophil-based gels are the most studied. A 2019 Cochrane review found vaginal moisturisers effective for mild to moderate GSM symptoms, though less effective than vaginal oestrogen for moderate to severe disease.
Lubricants are used at the time of sexual activity only. They reduce friction in the moment but do not address underlying atrophy. Water-based lubricants are safe with latex condoms; silicone-based last longer and are particularly useful for women with severe dryness; oil-based degrade latex and should be avoided with condoms. Using a lubricant at the time of intercourse is not a treatment for GSM, but it is an important quality-of-life measure while other interventions take effect.
Navigating GSM symptoms and not sure where to start? Dr. Suganya Venkat can help you understand which management level fits your situation. Message her directly on WhatsApp: wa.me/919940270499
Level 2: Vaginal oestrogen (the gold standard for moderate to severe GSM)
Vaginal oestrogen delivers low-dose oestrogen directly to the tissue that needs it, with very low systemic absorption. Both the American College of Obstetricians and Gynecologists (ACOG, 2020) and NAMS (2020) describe vaginal oestrogen as the most effective treatment for moderate to severe GSM, safe for long-term use in most women.
Available forms include vaginal cream (applied with an applicator or fingertip), pessaries or tablets (inserted with a small applicator), and the vaginal ring (replaced every three months). Systemic oestrogen absorption from these preparations is low, typically below five percent, meaning vaginal oestrogen does not substantially raise circulating oestrogen levels or carry the systemic risks associated with oral hormonal therapy.
For this reason, NAMS 2020 guidelines conclude that vaginal oestrogen may be considered by women who cannot use systemic MHT, including some women with a history of hormone-sensitive breast cancer, after discussion with their oncologist. This is a clinical decision that depends on individual circumstances.
Vaginal oestrogen requires a prescription and a conversation with your OB-GYN. Symptoms typically begin to improve within four to eight weeks, and full tissue restoration takes three to six months of consistent use. Many women use it long-term because GSM does not resolve when oestrogen remains low.
For the pelvic floor and bladder symptoms: Menopause Pelvic Floor: Why Muscles Weaken and What Helps and Menopause Bladder Leaks: Why It Happens and What Helps
Level 3: DHEA (prasterone)
Dehydroepiandrosterone (DHEA), when applied vaginally, is converted locally in vaginal tissue into both oestrogen and testosterone. This provides a different hormonal pathway to the same tissue effect as vaginal oestrogen.
Prasterone (marketed as Intrarosa in some countries) has been approved by the US FDA specifically for the dyspareunia (pain during intercourse) component of GSM (Labrie et al., 2016, Menopause). It is not yet widely available in India, but represents an emerging option for women who cannot or prefer not to use oestrogen-based preparations. Your OB-GYN will know the current availability and whether it is appropriate for your situation.
Level 4: Systemic menopausal hormone therapy (MHT)
When a woman has both GSM symptoms and significant vasomotor symptoms (hot flashes, night sweats, sleep disruption), systemic MHT addresses both. Systemic MHT raises circulating oestrogen, which reaches the genitourinary tissue indirectly.
Menolia’s content approach on systemic MHT is to acknowledge what it does, note who it might suit, and direct the clinical decision to your OB-GYN. The hot flash treatment post covers systemic MHT and the questions to bring to your doctor in full: Hot Flash Treatment: From Lifestyle to HRT.
Pelvic floor physiotherapy: the most underused intervention
Oestrogen decline reduces pelvic floor muscle tone and the collagen content that keeps those muscles elastic. The result is a combination of two patterns that require different approaches.
The first pattern is an underactive pelvic floor: muscles that are weakened and cannot generate enough closing force on the urethra and vaginal canal. This produces stress incontinence and, in some cases, pelvic organ prolapse.
The second pattern is an overactive pelvic floor: muscles that are too tight, often in response to protecting against pain or anticipating discomfort. This contributes to pain during intercourse even when adequate lubrication is present.
A 2010 Cochrane review by Dumoulin and Hay-Smith found pelvic floor muscle training significantly more effective than no treatment for stress and mixed urinary incontinence. A 2019 update of the same review confirmed the finding holds with strong evidence.
A pelvic floor physiotherapist assesses which pattern is present and designs treatment accordingly. Strengthening exercises (progressive versions of Kegel exercises, coordinated with breath) address underactivity. Relaxation techniques, stretching, and internal soft tissue work address overactivity. Most women with GSM have one or both components, and the assessment determines which.
For the UTI component specifically: Menopause and UTIs: Why They Keep Coming Back
Nutrition: what supports, what does not replace treatment
Food cannot reverse GSM, but certain foods support the tissue environment that treatment is working to restore.
Til (sesame seeds): Ground til is one of the richest accessible sources of lignans, a class of phytoestrogen. Lignans bind weakly to oestrogen receptors and may modulate some of the receptor-level changes associated with oestrogen deficiency. One tablespoon of ground til added to meals or mixed with warm water provides meaningful daily lignan intake.
Alsi (flaxseeds): The single richest dietary source of lignans. One tablespoon of freshly ground alsi daily, added to roti dough, warm water, or dahi, is the standard clinical recommendation. Grind fresh and refrigerate to preserve potency.
Dahi: Supports gut microbiome diversity, which has an indirect relationship with vaginal microbiome composition. Emerging research on the gut-to-vaginal microbiome axis suggests that gut Lactobacillus populations influence vaginal Lactobacillus populations over time, with diet as a shared regulator. Regular dahi consumption is a low-risk, high-value dietary habit regardless of whether the direct vaginal effect is confirmed in large trials.
Rajma and chana: Both contain isoflavones, a distinct class of phytoestrogen from lignans. Indian diets that regularly include dal, rajma, or chana provide a consistent low-level isoflavone intake that contributes to the overall phytoestrogen picture.
Haldi (turmeric): Curcumin, the bioactive compound in haldi, has anti-inflammatory properties studied across multiple tissue types. GSM involves a low-grade inflammatory component as the vaginal epithelium thins and pH rises. Cooking with haldi daily maintains anti-inflammatory support at the systemic level.
The practical limit: none of these foods replaces vaginal oestrogen for moderate to severe GSM. They are additions to a management plan, not substitutes for clinical treatment when symptoms are significantly affecting daily life.
When to see your OB-GYN
Bring GSM to your doctor when:
- Vaginal dryness or burning is present at rest, not only during sexual activity
- You have had two or more urinary tract infections in the past year with no other identified cause
- Urinary urgency or incontinence is affecting your work, sleep, or confidence in daily situations
- Sex has become uncomfortable enough to avoid
GSM responds well to treatment at every stage. Early treatment keeps the tissue in better condition and makes restoration faster. Women who wait several years often require a longer course of vaginal oestrogen before comfort is fully restored, and some structural narrowing may be harder to reverse. This is not a reason for alarm, but it is a reason not to wait.
Experiencing recurrent UTIs, ongoing vaginal discomfort, or bladder urgency in your forties or fifties? These symptoms have a shared cause and effective treatments. Message Dr. Suganya Venkat on WhatsApp to discuss what approach suits your specific situation: wa.me/919940270499
Frequently asked questions
What is genitourinary syndrome of menopause? Genitourinary syndrome of menopause (GSM) is the medical term for a cluster of symptoms affecting the vagina, urethra, and bladder that result from falling oestrogen levels during and after menopause. It includes vaginal dryness and burning, urinary urgency and recurrent UTIs, and sexual discomfort. The name was adopted in 2014 to replace the older term “vulvovaginal atrophy” because it better captures the full range of affected tissues and is less stigmatising.
Is GSM the same as vulvovaginal atrophy? Vulvovaginal atrophy (VVA) was the older term for vaginal tissue thinning due to oestrogen loss. GSM is the updated, broader term that also includes urinary and sexual symptoms. All women with VVA have GSM, but GSM additionally covers the bladder and urethral changes that occur alongside vaginal changes.
Does GSM improve on its own over time? Unlike vasomotor symptoms (hot flashes, night sweats), which often reduce as the body adjusts to lower oestrogen, GSM tends to progress without treatment because the genitourinary tissue continues to experience oestrogen deficiency. Early treatment slows progression and prevents more advanced atrophy. Waiting is generally not recommended, but it is also never too late to start.
Can I use vaginal oestrogen if I have a history of breast cancer? This question must be discussed with your oncologist and OB-GYN together. NAMS 2020 guidelines note that vaginal oestrogen has very low systemic absorption and may be appropriate for some breast cancer survivors when quality of life is significantly affected by GSM. The decision depends on cancer type, treatment history, and current hormonal status. There is no universal answer.
Are vaginal moisturisers the same as lubricants? No. Vaginal moisturisers are used regularly (two to three times a week or daily) to maintain vaginal tissue hydration over time. Lubricants are used during sexual activity to reduce friction in that moment. Both have a role in GSM management, but they do different things. Moisturisers address the underlying dryness; lubricants manage discomfort at a specific time. Neither treats the root cause of GSM, which is oestrogen deficiency.
At what age do Indian women typically develop GSM? Indian women reach menopause at an average age of 46 to 48, roughly four years earlier than the global average of 51. GSM develops during the perimenopause transition and progresses after the final menstrual period. Many Indian women begin noticing vaginal and urinary symptoms in their late forties. If you are in this age range and experiencing these changes, the timing is consistent with where oestrogen is in your body.
Does nutrition alone help with GSM? Nutrition supports but does not replace clinical management for moderate to severe GSM. Foods rich in phytoestrogens (til, alsi, rajma, chana) may provide mild supportive benefit by interacting weakly with oestrogen receptors. Dahi supports the gut microbiome, which may indirectly support vaginal pH balance. Haldi adds anti-inflammatory support. These foods complement a management plan, but cannot restore vaginal epithelium thickness or urethral integrity in the way that vaginal oestrogen does.
